For patients with schizophrenia being treated with antipsychotic drugs, the real-world rates of relapse are significantly higher than best-case rates because
A. best-case rates are promoted by pharmaceutical companies trying to market their drugs.
B. antipsychotic drugs only work for short periods of time.
C. the best-case rates are based on inaccurate assumptions about neurochemistry.
D. many patients stop taking their medication to avoid unpleasant side effects.